Association of omentin Val109Asp polymorphism with coronary artery disease

Objective: Coronary artery disease (CAD) is the most important morbidity and mortality disease in the world. It is also one of the leading causesof death in Turkey. Omentin, a recently found adipocytokine, is reported to regulate insulin sensitivity. It has anti-inflammatory properties and isinversely associated with CAD. Omentin gene polymorphism in patients with CAD has not been studied yet. The aim of this study is to investigatethe relationship between omentin Val109Asp polymorphism and CAD.Methods: This is an observational study on genetic association. 157 consecutive patients who had undergone coronary angiography wereincluded in the study. Seventy-five of them had CAD and the rest serves the control group. Val109Asp polymorphism was analyzed and com-pared. Chi-square test was used in comparison of genotype frequencies, whereas ANOVA and chi-square tests were used in comparison ofclinical characteristics according to the genotypes.Results: There was no significant difference between CAD patients and control subjects regarding omentin Val109Asp polymorphism. However, a 2.5fold increase in Val/Val (homozygous mutant) genotype was detected in patients with CAD. The OR (80% Cl) for Val/Val genotype was 3.46 (1.14-10.49).Conclusion: Although no significant difference was detected regarding omentin Val109Asp polymorphism, Val/Val genotype frequency was found to bemore in patient group than control group. In conclusion, it may be speculated that Val/Val genotype increases the tendency for CAD, but this experimentshould done with larger population to clarify this issue.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245. [CrossRef]
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95. [CrossRef]
3. Miyoshi T, Doi M, Hirohata S, Sakane K, Kamikawa S, Kitawaki T, et al. Cardio-ankle vascular index is independently associated with the severity of coronary atherosclerosis and left ventricular function in patients with ischemic heart disease. J Atheroscler Thromb 2010; 17: 249-58. [CrossRef]
4. Kajiya M, Miyoshi T, Doi M, Usui S, Iwamoto M, Takeda K, et al. Serum adipocyte fatty acid-binding protein is independently associated with complex coronary lesions in patients with stable coronary artery disease. Heart Vessels 2013; 28: 696-703. [CrossRef]
5. Yaykasli KO, Dogan M, Kaya E, Ozsahin M, Yaykasli E, Ataoglu S, Yuce H. The upregulation of matrix metalloproteinase-2 and -9 genes caused by resistin in human chondrocytes, Acta Medica Anatolia 2014; 2(1): 19-23. [CrossRef]
6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30. [CrossRef]
7. Alçelik A, Tosun M, Özlü MF, Eroğlu M, Aktaş G, Kemahli E, et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res 2012; 35: 511-6. [CrossRef]
8. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-61. [CrossRef]
9. Kralisch S, Klein J, Bluher M, Paschke R, Stumvoll M, Fasshauer M, et al. Therapeutic perspectives of adipocytokines. Expert Opin Pharmacother 2005; 6: 863-72. [CrossRef]
10. Yang RZ, Shuldiner AR, Gong DW. Cloning of omentin, a new adipokine from human omental fat tissue. NCBI nucleotide database, 2003; Accession Number: AY549722.
11. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011; 32: 873-8. [CrossRef]
12. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataovka Y, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011; 219: 811-4. [CrossRef]
13. Soydinç S, Çelik A, Ermiyürek S, Davutoğlu V, Tarakçıoğlu M, Aksoy M. The relationship between oxidative stress, nitric oxide, and coronary artery disease. Eur J Gen Med 2007; 4:62-6.
14. Turan H, Yaykaşlı KO, Soğuktaş H, Yaykaşlı E, Aliağaoğlu C, Erdem T, et al. Omentin serum levels and omentin gene Val109Asp polymorphism in patients with psoriasis. Int J Dermatol 2014; 53: 601-5. [CrossRef]
15. Yaykasli KO, Rheumatoid arthritis and adipokines. Eur J Basic Med Sci 2013; 3(2): 38-43.
16. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-56. [CrossRef]
17. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010; 2010: 535918.
18. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009; 53: 167-75. [CrossRef]
19. Ding Q, White SP, Ling C, Zhou W. Resistin and cardiovascular disease. Trends Cardiovasc Med 2011; 21: 20-7. [CrossRef]
20. Shams M, Rasekhi Kazerouni A, Ostovan MA, Omrani GR. The relationship between serum adiponectin levels with the presence and severity of coronary artery disease. Arch Iran Med 2012; 15: 611-6.
21. Yan JJ, Tang NP, Tang JJ, Jia EZ, Wang MW, Wang QM, et al. Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population. Clin Chim Acta 2010; 411: 26-30. [CrossRef]
22. Zhang H, Cui J, Zhang C. Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol 2010; 2: 370-6. [CrossRef]
23. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143-8. [CrossRef]
24. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity 2011; 19: 1552-9. [CrossRef]
25. Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011; 93: 21-5. [CrossRef]
26. De Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-61. [CrossRef]
27. Shang FJ, Wang JP, Liu XT, Zheng QS, Xue YS, Wang B, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011; 16: 657-62. [CrossRef]

APA	YÖRÜK Ü, YAYKAŞLI K, özhan h, Memişoğulları R, Karabacak A, BULUR S, ASLANTAŞ Y, BAŞAR C, Kaya E (2014). Association of omentin Val109Asp polymorphism with coronary artery disease. , 511 - 514.
Chicago	YÖRÜK Ümit,YAYKAŞLI Kürşat Oğuz,özhan hakan,Memişoğulları Ramazan,Karabacak Ahmet,BULUR Serkan,ASLANTAŞ Yusuf,BAŞAR Cengiz,Kaya Ertugrul Association of omentin Val109Asp polymorphism with coronary artery disease. (2014): 511 - 514.
MLA	YÖRÜK Ümit,YAYKAŞLI Kürşat Oğuz,özhan hakan,Memişoğulları Ramazan,Karabacak Ahmet,BULUR Serkan,ASLANTAŞ Yusuf,BAŞAR Cengiz,Kaya Ertugrul Association of omentin Val109Asp polymorphism with coronary artery disease. , 2014, ss.511 - 514.
AMA	YÖRÜK Ü,YAYKAŞLI K,özhan h,Memişoğulları R,Karabacak A,BULUR S,ASLANTAŞ Y,BAŞAR C,Kaya E Association of omentin Val109Asp polymorphism with coronary artery disease. . 2014; 511 - 514.
Vancouver	YÖRÜK Ü,YAYKAŞLI K,özhan h,Memişoğulları R,Karabacak A,BULUR S,ASLANTAŞ Y,BAŞAR C,Kaya E Association of omentin Val109Asp polymorphism with coronary artery disease. . 2014; 511 - 514.
IEEE	YÖRÜK Ü,YAYKAŞLI K,özhan h,Memişoğulları R,Karabacak A,BULUR S,ASLANTAŞ Y,BAŞAR C,Kaya E "Association of omentin Val109Asp polymorphism with coronary artery disease." , ss.511 - 514, 2014.
ISNAD	YÖRÜK, Ümit vd. "Association of omentin Val109Asp polymorphism with coronary artery disease". (2014), 511-514.

APA	YÖRÜK Ü, YAYKAŞLI K, özhan h, Memişoğulları R, Karabacak A, BULUR S, ASLANTAŞ Y, BAŞAR C, Kaya E (2014). Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyoloji Dergisi, 14(6), 511 - 514.
Chicago	YÖRÜK Ümit,YAYKAŞLI Kürşat Oğuz,özhan hakan,Memişoğulları Ramazan,Karabacak Ahmet,BULUR Serkan,ASLANTAŞ Yusuf,BAŞAR Cengiz,Kaya Ertugrul Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyoloji Dergisi 14, no.6 (2014): 511 - 514.
MLA	YÖRÜK Ümit,YAYKAŞLI Kürşat Oğuz,özhan hakan,Memişoğulları Ramazan,Karabacak Ahmet,BULUR Serkan,ASLANTAŞ Yusuf,BAŞAR Cengiz,Kaya Ertugrul Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyoloji Dergisi, vol.14, no.6, 2014, ss.511 - 514.
AMA	YÖRÜK Ü,YAYKAŞLI K,özhan h,Memişoğulları R,Karabacak A,BULUR S,ASLANTAŞ Y,BAŞAR C,Kaya E Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyoloji Dergisi. 2014; 14(6): 511 - 514.
Vancouver	YÖRÜK Ü,YAYKAŞLI K,özhan h,Memişoğulları R,Karabacak A,BULUR S,ASLANTAŞ Y,BAŞAR C,Kaya E Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyoloji Dergisi. 2014; 14(6): 511 - 514.
IEEE	YÖRÜK Ü,YAYKAŞLI K,özhan h,Memişoğulları R,Karabacak A,BULUR S,ASLANTAŞ Y,BAŞAR C,Kaya E "Association of omentin Val109Asp polymorphism with coronary artery disease." Anadolu Kardiyoloji Dergisi, 14, ss.511 - 514, 2014.
ISNAD	YÖRÜK, Ümit vd. "Association of omentin Val109Asp polymorphism with coronary artery disease". Anadolu Kardiyoloji Dergisi 14/6 (2014), 511-514.